{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:31:19Z","timestamp":1793946679085,"version":"4.8.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eclinm.2026.104199","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:10:53Z","timestamp":1789506653000},"page":"104199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacological considerations for prescribing of small molecule inhibitors in patients with non-small cell lung cancer"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6948-4442","authenticated-orcid":false,"given":"Lotte M.G.","family":"Hulskotte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.D. Marijn","family":"Veerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan A.C.","family":"Lanser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-7816","authenticated-orcid":false,"given":"Anna K.L.","family":"Reyners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Taxis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-9578","authenticated-orcid":false,"given":"Frank G.A.","family":"Jansman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.eclinm.2026.104199_bib1","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1200\/JCO-25-02822","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, 2026.3.0","volume":"44","author":"Puri","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104199_bib2","series-title":"Therapy for stage IV non\u2013small cell lung cancer with driver alterations: ASCO living guideline","author":"Puri","year":"2026"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104199_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.104199_bib4","series-title":"ESMO living guideline: oncogene-addicted metastatic non-small cell lung cancer","author":"Hendriks","year":"2026"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104199_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104199_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17425255.2023.2277758","article-title":"Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics","volume":"19","author":"Sarah","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104199_bib7","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104199_bib8","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S1470-2045(20)30069-3","article-title":"Clinical implications of food-drug interactions with small-molecule kinase inhibitors","volume":"21","author":"Veerman","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104199_bib9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nrclinonc.2014.40","article-title":"Determining the optimal dose in the development of anticancer agents","volume":"11","author":"Mathijssen","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104199_bib10","article-title":"Hypoalbuminemia and pharmacokinetics: when the misunderstanding of a fundamental concept leads to repeated errors over decades","volume":"12","author":"Gandia","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104199_bib11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2215\/CJN.0000000000000395","article-title":"Pharmacology of tyrosine kinase inhibitors: implications for patients with kidney diseases","volume":"19","author":"Hulin","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.eclinm.2026.104199_bib12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejpb.2016.11.034","article-title":"Food, gastrointestinal pH, and models of oral drug absorption","volume":"112","author":"Abuhelwa","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.eclinm.2026.104199_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100832","article-title":"Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer","volume":"62","author":"Heersche","year":"2022","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.eclinm.2026.104199_bib16","series-title":"Guideline on the investigation of bioequivalence","year":"2010"},{"key":"10.1016\/j.eclinm.2026.104199_bib17","series-title":"Bioavailability and bioequivalence studies for orally administered drug products \u2014 general considerations","year":"2014"},{"key":"10.1016\/j.eclinm.2026.104199_bib18","series-title":"Chapter 1: pharmacokinetics & pharmacodynamics","article-title":"Nursing pharmacology","author":"Ernstmeyer","year":"2023"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104199_bib19","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jtho.2017.07.005","article-title":"ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC)","volume":"12","author":"Cho","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104199_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40262-020-00910-1","article-title":"Influence of cow\u2019s milk and esomeprazole on the absorption of erlotinib: a randomized, crossover pharmacokinetic study in lung cancer patients","volume":"60","author":"Veerman","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104199_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/CAD.0b013e3282f2d8e4","article-title":"Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals","volume":"19","author":"Ling","year":"2008","journal-title":"Anticancer Drugs"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104199_bib22","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1021\/acs.molpharmaceut.5c00832","article-title":"Relative bioavailability of zongertinib, an orally administered HER2-Selective tyrosine kinase inhibitor, under fed and fasted conditions in healthy Male participants: results from two randomized, open-label, crossover studies","volume":"22","author":"Pereira","year":"2025","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104199_bib23","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/cts.13515","article-title":"Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling","volume":"16","author":"Liu","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104199_bib24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.6004\/jnccn.2023.7017","article-title":"Influence of food with different fat concentrations on alectinib exposure: a randomized crossover pharmacokinetic trial","volume":"21","author":"Lanser","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104199_bib25","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2023.03.020","article-title":"Analysis of serious weight gain in patients using alectinib for ALK-positive lung cancer","volume":"18","author":"de Leeuw","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104199_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cpdd.1489","article-title":"Impact of acid-reducing agents on sotorasib pharmacokinetics and potential mitigation of the impact by coadministration with an acidic beverage","volume":"14","author":"Cardona","year":"2025","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104199_bib27","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2015.65.2560","article-title":"Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer","volume":"34","author":"van Leeuwen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104199_bib28","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40262-016-0503-3","article-title":"Tyrosine kinase inhibitors and proton pump inhibitors: an evaluation of treatment options","volume":"56","author":"van Leeuwen","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eclinm.2026.104199_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2023.1137637","article-title":"Ocular surface complications following biological therapy for cancer","volume":"5","author":"Ma","year":"2023","journal-title":"Front Toxicol"},{"key":"10.1016\/j.eclinm.2026.104199_bib30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2017.12.011","article-title":"Current perspective: osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring","volume":"91","author":"Schiefer","year":"2018","journal-title":"Eur J Cancer"},{"issue":"48","key":"10.1016\/j.eclinm.2026.104199_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018131","article-title":"Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer: clinical and radiologic characteristics and risk factors","volume":"98","author":"Hwang","year":"2019","journal-title":"Medicine (Baltim)"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104199_bib32","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00280-019-03788-4","article-title":"Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer","volume":"83","author":"Kawata","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104199_bib33","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jtho.2018.11.022","article-title":"Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib","volume":"14","author":"Gemma","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104199_bib34","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1016\/j.cllc.2025.05.015","article-title":"Osimertinib as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting: updated overall survival data (OSI-FACT-OS)","volume":"26","author":"Sakata","year":"2025","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104199_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103642","article-title":"Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study","volume":"9","author":"Niho","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104199_bib36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10147-019-01439-5","article-title":"Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib","volume":"24","author":"Tamura","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104199_bib37","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1111\/cas.70400","article-title":"Afatinib versus osimertinib for non-small cell lung cancer with uncommon EGFR mutations: real-world outcomes","volume":"117","author":"Nagano","year":"2026","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104199_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11523-024-01048-x","article-title":"Real-World data on subsequent therapy for first-line osimertinib-induced pneumonitis: safety of EGFR-TKI rechallenge (Osi-risk study TORG-TG2101)","volume":"19","author":"Nishioka","year":"2024","journal-title":"Target Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104199_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.15507","article-title":"Real-World study of EGFR-TKI rechallenge with another TKI after first-line osimertinib discontinuation in patients with EGFR-mutated non-small cell lung cancer: a subset analysis of the reiwa study","volume":"16","author":"Sonehara","year":"2025","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104199_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/oby.22378","article-title":"Obesity as a disease: the obesity society 2018 position statement","volume":"27","author":"Jastreboff","year":"2019","journal-title":"Obesity"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104199_bib41","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.annonc.2020.05.006","article-title":"Characterization of on-target adverse events caused by TRK inhibitor therapy","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104199_bib42","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/s41467-020-15537-w","article-title":"TrkB-expressing paraventricular hypothalamic neurons suppress appetite through multiple neurocircuits","volume":"11","author":"An","year":"2020","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104199_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf287","article-title":"Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in The CROWN study","volume":"30","author":"Liu","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.eclinm.2026.104199_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108034","article-title":"Lorlatinib-associated weight gain and dyslipidaemia: a retrospective analysis and implications for future care","volume":"198","author":"John","year":"2024","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104199_bib45","article-title":"Early weight gain as a risk factor for increased maximum weight gain among patients with NSCLC on lorlatinib and other ALK tyrosine kinase inhibitors","volume":"6","author":"Watson","year":"2025","journal-title":"JTO Clin Res Rep"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104199_bib46","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1200\/JCO-24-01579","article-title":"Body weight gain associated with alectinib in patients with ALK+ non-small cell lung cancer: pooled analysis of individual patient data from four prospective clinical trials","volume":"43","author":"Sikkema","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104199_bib47","article-title":"Meta-analysis exploring tyrosine kinase inhibitor-induced weight gain in oncogene-addicted NSCLC","volume":"6","author":"Scaglione","year":"2025","journal-title":"JTO Clin Res Rep"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104199_bib48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO-24-02514","article-title":"ALK tyrosine kinase inhibitors induced weight gain: more refined definition of weight gain, glucagon-like Peptide-1 agonist treatment, and therapeutic drug monitoring of ALK+ non-small cell lung cancer?","volume":"43","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104199_bib49","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/cac2.70030","article-title":"Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study","volume":"45","author":"Heersche","year":"2025","journal-title":"Cancer Commun"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104199_bib50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jamaophthalmol.2023.6089","article-title":"Epidermal growth factor receptor inhibitors for lung cancer and the risk of keratitis","volume":"142","author":"Huang","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.eclinm.2026.104199_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jtos.2024.03.008","article-title":"New-onset keratitis associated with epidermal growth factor receptor-based targeted therapies in han Chinese patients with lung cancer: a multi-center cohort study","volume":"33","author":"Ma","year":"2024","journal-title":"Ocul Surf"},{"key":"10.1016\/j.eclinm.2026.104199_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920907543","article-title":"Corneal side effects induced by EGFR-inhibitor antibody-drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study","volume":"12","author":"Parrozzani","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.eclinm.2026.104199_bib53","article-title":"Ophthalmic adverse effects of BRAF inhibitors","volume":"11","author":"Castillejo Becerra","year":"2022","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104199_bib54","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.survophthal.2020.01.002","article-title":"Steroid-induced glaucoma: epidemiology, pathophysiology, and clinical management","volume":"65","author":"Roberti","year":"2020","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104199_bib55","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/cts.13662","article-title":"Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations","volume":"16","author":"Hahn","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.eclinm.2026.104199_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107535","article-title":"A pragmatic guide for management of adverse events associated with lorlatinib","volume":"191","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104199_bib57","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyag137","article-title":"Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis","volume":"31","author":"Drilon","year":"2026","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104199_bib58","first-page":"385","article-title":"Incidence and management of pyrexia syndrome in patients treated with dabrafenib and trametinib: a retrospective study","volume":"34","author":"Komisarof","year":"2026","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104199_bib59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104199_bib60","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JOP.19.00652","article-title":"Management of cancer therapy-associated oral mucositis","volume":"16","author":"Brown","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104199_bib61","article-title":"Drug-induced inflammatory colitis: a review of novel agents","volume":"3","author":"Terlato","year":"2026","journal-title":"npj Gut Liver"},{"key":"10.1016\/j.eclinm.2026.104199_bib62","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/354657","article-title":"Treatment of non-small-cell lung cancer with erlotinib following gefitinib-induced hepatotoxicity: review of 8 clinical cases","volume":"2012","author":"Yano","year":"2012","journal-title":"Lung Cancer Int"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104199_bib63","first-page":"5211","article-title":"Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity","volume":"34","author":"Yonesaka","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eclinm.2026.104199_bib64","article-title":"Adagrasib treatment after Sotorasib-Related hepatotoxicity in patients with KRAS(G12C)-Mutated non-small cell lung cancer: a case series and literature review","volume":"8","author":"Luo","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"19","key":"10.1016\/j.eclinm.2026.104199_bib65","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1200\/JCO.2010.34.3368","article-title":"Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism","volume":"29","author":"Kijima","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:52:46Z","timestamp":1793944366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026004529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":63,"alternative-id":["S2589537026004529"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104199","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological considerations for prescribing of small molecule inhibitors in patients with non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104199"}}